| Identification | Back Directory | [Name]
4-(5-Amino-2-pyridin-3-yl-thiazolo[5,4-d]pyrimidin-7-yl)-piperazine-1-carboxylic acid p-tolylamide | [CAS]
1245319-54-3 | [Synonyms]
PI4KIII β inhibitor 3
PI4KIII beta inhibitor 3
PI-4KIII beta inhibitor 3,PI4KIII beta inhibitor 3
4-(5-aMino-2-(pyridin-3-yl)thiazolo[5,4-d]pyriMidin-7-yl)-N-p-tolylpiperazine-1-carboxaMide
4-(5-Amino-2-pyridin-3-yl-thiazolo[5,4-d]pyrimidin-7-yl)-piperazine-1-carboxylic acid p-tolylamide
1-Piperazinecarboxamide, 4-[5-amino-2-(3-pyridinyl)thiazolo[5,4-d]pyrimidin-7-yl]-N-(4-methylphenyl)- | [Molecular Formula]
C22H22N8OS | [MDL Number]
MFCD22124455 | [MOL File]
1245319-54-3.mol | [Molecular Weight]
446.53 |
| Chemical Properties | Back Directory | [density ]
1.432±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
13.95±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
PI4KIII beta inhibitor 3 is a novel and high effective PI4KIIIβ inhibitor with IC50 of 5.7 nM. | [in vivo]
PI4KIII beta inhibitor 3 (40 mg/kg per day, n=12) is able to delay the onset of arthritic symptoms and also to decrease symptom severity in a preventive model of arthritis compared to a vehicle control (MC 1%, n=12). PI4KIII beta inhibitor 3 reduces the anti-CII IgG titre and histological scores in the collagen-induced arthritis mouse model. Oral administration of PI4KIII beta inhibitor 3 results in prolonged graft survival in 3 out of 6 grafts in each group at day 30. Several grafts continued beating after withdrawal of the treatment (up to 60 days), indicating the induction of a certain type of graft tolerance. To evaluate the operational tolerance phenotype, animals with functional graft at day 60 are challenged with a second graft from the same donor strain or from a third party. No treatment is applied. The second grafts from the third party are rejected at day 8 (n=2) whereas second grafts from the same donor strain are functional for more than 90 days (n=2)[1]. | [IC 50]
PI4KIIIβ: 5.7 nM (IC50) | [References]
[1] Jean Herman, et al. Autoimmune and inflammatory disorder therapy. From PCT Int. Appl. (2013), WO 2013034738 A1 |
|
| Company Name: |
China Langchem Inc.
|
| Tel: |
0086-21-58956006 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList19141/0_EN.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|